These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 20195775)

  • 1. Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.
    Slater EP; Langer P; Fendrich V; Habbe N; Chaloupka B; Matthäi E; Sina M; Hahn SA; Bartsch DK
    Fam Cancer; 2010 Sep; 9(3):335-43. PubMed ID: 20195775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A germline mutations in familial pancreatic cancer.
    Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H
    Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience.
    Schneider R; Slater EP; Sina M; Habbe N; Fendrich V; Matthäi E; Langer P; Bartsch DK
    Fam Cancer; 2011 Jun; 10(2):323-30. PubMed ID: 21207249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA2 germline mutations in familial pancreatic carcinoma.
    Hahn SA; Greenhalf B; Ellis I; Sina-Frey M; Rieder H; Korte B; Gerdes B; Kress R; Ziegler A; Raeburn JA; Campra D; Grützmann R; Rehder H; Rothmund M; Schmiegel W; Neoptolemos JP; Bartsch DK
    J Natl Cancer Inst; 2003 Feb; 95(3):214-21. PubMed ID: 12569143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
    Zhen DB; Rabe KG; Gallinger S; Syngal S; Schwartz AG; Goggins MG; Hruban RH; Cote ML; McWilliams RR; Roberts NJ; Cannon-Albright LA; Li D; Moyes K; Wenstrup RJ; Hartman AR; Seminara D; Klein AP; Petersen GM
    Genet Med; 2015 Jul; 17(7):569-77. PubMed ID: 25356972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of familial pancreatic cancer in Germany.
    Bartsch DK; Sina-Frey M; Ziegler A; Hahn SA; Przypadlo E; Kress R; Gerdes B; Rieder H
    Pancreatology; 2001; 1(5):510-6. PubMed ID: 12120230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
    Ghiorzo P; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bernard L; Bonelli L; Borgonovo G; Bruno W; De Cian F; Decensi A; Filauro M; Faravelli F; Gozza A; Gargiulo S; Mariette F; Nasti S; Pastorino L; Queirolo P; Savarino V; Varesco L; Scarrà GB;
    J Med Genet; 2012 Mar; 49(3):164-70. PubMed ID: 22368299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of BRCA2 mutations in familial pancreatic cancer.
    Couch FJ; Johnson MR; Rabe KG; Brune K; de Andrade M; Goggins M; Rothenmund H; Gallinger S; Klein A; Petersen GM; Hruban RH
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):342-6. PubMed ID: 17301269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history.
    Chaffee KG; Oberg AL; McWilliams RR; Majithia N; Allen BA; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Petersen GM
    Genet Med; 2018 Jan; 20(1):119-127. PubMed ID: 28726808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.
    Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ
    J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families.
    Bartsch DK; Langer P; Habbe N; Matthäi E; Chaloupka B; Sina M; Hahn SA; Slater EP
    Clin Genet; 2010 Apr; 77(4):333-41. PubMed ID: 20041885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis.
    Limijadi EKS; Muniroh M; Prajoko YW; Tjandra KC; Respati DRP
    PLoS One; 2024; 19(5):e0299276. PubMed ID: 38809921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.
    Earl J; Galindo-Pumariño C; Encinas J; Barreto E; Castillo ME; Pachón V; Ferreiro R; Rodríguez-Garrote M; González-Martínez S; Ramon Y Cajal T; Diaz LR; Chirivella-Gonzalez I; Rodriguez M; de Castro EM; García-Seisdedos D; Muñoz G; Rosa JMR; Marquez M; Malats N; Carrato A
    EBioMedicine; 2020 Mar; 53():102675. PubMed ID: 32113160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. German national case collection of familial pancreatic cancer - clinical-genetic analysis of the first 21 families.
    Rieder H; Sina-Frey M; Ziegler A; Hahn SA; Przypadlo E; Kress R; Gerdes B; Colombo Benkmann M; Eberl T; Grützmann R; Lörken M; Schmidt J; Bartsch DK
    Onkologie; 2002 Jun; 25(3):262-6. PubMed ID: 12119461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
    Murphy KM; Brune KA; Griffin C; Sollenberger JE; Petersen GM; Bansal R; Hruban RH; Kern SE
    Cancer Res; 2002 Jul; 62(13):3789-93. PubMed ID: 12097290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
    Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
    Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline mutations in Japanese familial pancreatic cancer patients.
    Takai E; Yachida S; Shimizu K; Furuse J; Kubo E; Ohmoto A; Suzuki M; Hruban RH; Okusaka T; Morizane C; Furukawa T
    Oncotarget; 2016 Nov; 7(45):74227-74235. PubMed ID: 27732944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
    Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
    Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.